Lenalidomide Maintenance Post-debulking in Advanced CTCL
Lenalidomide Maintenance Post-debulking in Advanced CTCL
RATIONALE: Observation is watching a patient's condition but not giving treatment unless
 symptoms appear or change. Lenalidomide may stop the growth of cancer cells by blocking blood
 flow to the cancer. It is not yet known whether observation or lenalidomide is more effective
 in treating patients who are in complete or partial response after receiving previous
 gemcitabine hydrochloride or doxorubicin hydrochloride liposome for cutaneous T-cell lymphoma
 or mycosis fungoides/Sézary syndrome.

 PURPOSE: This randomized phase III trial is studying observation to see how well it works
 compared with lenalidomide in treating patients who are in complete or partial response after
 receiving previous gemcitabine hydrochloride or doxorubicin hydrochloride liposome for stage
 IIB, stage III, or stage IV cutaneous T-cell lymphoma or stage IIB, stage III, or stage IV
 mycosis fungoides/Sézary syndrome.
OBJECTIVES:

 -  To determine if observation versus lenalidomide maintenance therapy after debulking with
 gemcitabine hydrochloride or pegylated liposomal doxorubicin hydrochloride with or
 without radiotherapy prolongs progression-free survival of patients with advanced stage
 IIIB or IV T-cell cutaneous lymphoma or mycosis fungoides/Sézary syndrome not previously
 treated with other intravenous chemotherapy.

 OUTLINE: This is a multicenter study. Patients are stratified according to institution,
 response to debulking treatment (complete response vs partial response), and disease (mycosis
 fungoides [MF] vs erythrodermic MF/Sézary syndrome). Patients are randomized to 1 of 2
 treatment arms.

 -  Arm I: Beginning 4-6 weeks after completion of prior debulking therapy, patients undergo
 observation for 560 days.

 -  Arm II: Beginning 4-6 weeks after completion of prior debulking therapy, patients
 receive oral lenalidomide once a day on days 1-21. Treatment repeats every 28 days for
 20 courses in the absence of disease progression or unacceptable toxicity.

 After completion of study treatment, patients are followed at 4 weeks and then every 12 weeks
 thereafter.
DISEASE CHARACTERISTICS:

 -  Diagnoses of advanced T-cell cutaneous lymphoma or mycosis fungoides/Sézary syndrome

 -  Stage IIB-IV disease

 -  Achieved complete or partial response after undergoing prior debulking therapy with 1
 of the following recommended* regimens with or without radiotherapy**:

 -  Gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of a 28-day
 course at a dose of 1,000 to 1,200 mg/m² for a total of four courses

 -  Pegylated liposomal doxorubicin hydrochloride IV over 1 hour on days 1 and 15 of
 a 28-day course at a dose of 20 mg/m² for a total of four courses NOTE: *These
 recommended regimens can be altered according to local institutional policies. In
 case of drug intolerance, the study regimen can be switched from one regimen to
 the other.

 NOTE: **Local low-dose/energy-ionizing radiation therapy allowed as part of the debulking
 process to treat lesions that do not respond after 3 courses of debulking chemotherapy.

 -  Sézary cell burden must be decreased by at least 50% after debulking in patients with
 Sézary syndrome

 -  Disease not appropriate for skin-directed therapy per local institution standards

 -  No disease progression between registration and randomization

 -  No CNS involvement

 PATIENT CHARACTERISTICS:

 -  WHO performance status 0-2

 -  Life expectancy > 12 months

 -  Hemoglobin ≥ 10 g/dL

 -  Absolute neutrophil count ≥ 1.5 x 10^9/L

 -  Platelet count ≥ 60 x 10^9/L

 -  Total bilirubin ≤ 1.5 times upper limit of normal (UNL)

 -  Alkaline phosphatase ≤ 3 times UNL

 -  ALT/AST ≤ 3 times UNL

 -  Electrolytes (including sodium, potassium, and chloride) normal

 -  Creatinine normal

 -  Creatinine clearance ≥ 60 mL/min

 -  Uric acid and calcium normal

 -  Free T4 and TSH ≤ 1.5 times ULN

 -  Patients with a buffer range from the normal values of +/- 10% for hematology and
 biochemistry are acceptable

 -  Not pregnant or nursing

 -  Negative pregnancy test

 -  Fertile patients must use effective contraception 4 weeks prior to, during, and for 4
 weeks after completion of study therapy

 -  Males must agree not to donate semen during and for 1 week after completion of study
 therapy

 -  Patients with high risk for or history of a thromboembolic event must agree to receive
 prophylactic anticoagulation therapy (e.g., vitamin K) to keep INR in the range of 2-3

 -  No New York Heart Association class III-IV disease

 -  No blood donating during and for 1 week after completion of study therapy

 -  No uncontrolled infectious disease, autoimmune disease, or immunodeficiency

 -  No second malignancies within the past 3 years except surgically cured carcinoma in
 situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b
 prostate cancer, and basal or squamous cell carcinoma of the skin

 -  No psychological, familial, sociological, or geographical condition potentially
 hampering compliance with the study protocol and follow-up schedule

 -  No Lapp lactase deficiency or history of glucose-galactose malabsorption

 PRIOR CONCURRENT THERAPY:

 -  See Disease Characteristics

 -  No other prior intravenous chemotherapy for this cancer

 -  For purposes of this protocol, the definition of intravenous chemotherapy also
 includes denileukin diftitox, antibodies, or antibody conjugates

 -  No prior splenectomy or splenic irradiation

 -  No concurrent topical corticosteroids

 -  Concurrent systemic corticosteroids allowed for treatment of tumor flare
 reactions

 -  No radiation or drug-based therapy (including steroids) between registration and
 randomization

 -  No other concurrent drugs (including steroids) during the debulking regimen

 -  Low-dose steroids as premedication allowed at the investigator's discretion

 -  No other concurrent anticancer treatments